**1. Introduction**

506 Advances in Cancer Therapy

Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., & Carbone,

Perea, G., Lasa, A., Aventín, A., Domingo, A., Villamor, N., Queipo, de Llano, M.P., Llorente,

inv(16)]. *Leukemia,* Vol. 20, No.1*, (*January 2006*),* pp.87-94, ISSN 0887-6924 Piccirillo, J.F., Tierney, R.M., Costas, I., Grove, L., & Spitznagel, E.L. Jr.(2004). Prognostic

Radich, J.P., Gehly, G., Gooley, T., Bryant, E., Clift, R.A., Collins, S., Edmands, S., Kirk, J.,

Schlenk, R.F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank,

Schoch, C., Schnittger, S., Kern, W., Lengfelder, E., Löffler, H., Hiddemann, W., & Haferlach,

Stelzer, G.T., & Goodpasture, L. (2000). Use of multiparameter flow cytometry and

Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman,

Wang, Z.Y., & Chen, Z. (2008). Acute promyelocytic leukemia: from highly fatal to highly curable. *Blood,* Vol. 111, No. 5 (March 2008), pp.2505-15, ISSN 0006-4971

238,Wiley-Liss, ISBN 0-471-23957-7, United States of America

Edition*,* IARC, WHO Press, ISBN 9789283224310, Geneva, Switzerland Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris,

No.1(2), pp:36-43, ISSN 1857-5749

pp.2632-2638, ISSN 0006-4971

2005), pp.2912-2919, ISSN 0006-4971

937–951, ISSN 0006-4971

20, (May 2004), pp.2441-2447, ISSN 0098-7484

P.P. (1982). Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. *Am J Clin Oncol,* Vol.5, No.6, (December 1982), pp.649-655, ISSN 0002-9173 Panovska-Stavridis, I., Cevreska, L., Trajkova, S., Hadzi-Pecova, L., Trajkov, D., Petlickovski,

A., Srbinovska, O., Matevska, N., Dimovski, A., & Spiroski, M. (2008). Preliminary results of introducing the method multiparameter flow cytometry in patients with acute leukemia in the Republic of Macedonia. *Macedonian Journal of Medical Sciences,* 

A., Juncà, J., Palacios, C., Fernández, C., Gallart, M., Font, L., Tormo, M., Florensa, L., Bargay, J., Martí, J.M., Vivancos, P., Torres, P., Berlanga, J.J., Badell, I., Brunet, S., Sierra, J., & Nomdedéu, J.F.; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel.(2006). Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogeneticst(8;21) and

importance of comorbidity in a hospital-based cancer registry. *JAMA,* Vol. 291, No.

Lee, A., Kessler, P., et al. (1995). Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. *Blood,* Vol. 85, No. 9, (May 1995),

M., Späth, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A., & Döhner, H.; German-Austrian Acute Myeloid Leukemia Study Group. (2008). Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. Vol. 358, No. 18, (May 2008), pp.1909–1918, ISSN 0028-4793

T. (2002). Rapid diagnostic approach to PML–RAR alpha-positive acute promyelocytic leukemia. *Hematol J* ,Vol.3, No.5, (2002), pp.259–263, ISSN 1466-4860 Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G., Storer,

B.(2005). Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*. Vol. 106, No.8, (October

immunophenotyping for the diagnosis and classification of acute myeloid leukemia, In *Immunophenotyping,* Stewarat C,S & Nicholson J.K.A.,pp.215-

J.W. (2008). *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues,* Fourth

N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A., & Bloomfield, C.D.(2009). The 2008 revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia: rationale and important changes. *Blood*, Vol. 114, No.5, (July 2009), pp. Research of interactions between Electromagnetic (EM) Field and biological systems is of growing interests elsewhere. In this area of research very important activity are studies of prospective medical applications of microwaves (i.e. a possibility to use microwave energy and/or microwave technique and technology for treatment purposes) are a quite new and a very rapidly developing field. Microwave thermotherapy is being used in medicine for the cancer treatment and for some other diseases since early eighties. Most common methods used for treatment of cancer are radiotherapy and chemotherapy. These therapeutic methods have many undesirable effects, such as usage of ionizing radiation. Another method used for treatment of cancer is hyperthermia. This method is based on the principle of destruction of malignant cells by artificially increased temperature in the temperature range between 41 and 45 ºC fails self-protective mechanism of malignant cells. In contrast with chemotherapy and radiotherapy, hyperthermia is not limited by the number of doses of radiation.
